Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. on January 22, 2019. The filing addresses preliminary financial results for the year ended December 31, 2018, and the announcement of updated clinical data for the company's pancreatic cancer candidate, RX-3117. Note: The input metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
- Cash Position: The company expects to report approximately $14.7 million in cash, cash equivalents, and investments as of December 31, 2018.
- Revenue, Profit, and Margins: The filing text does not provide clear values for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: No specific debt figures are disclosed; liquidity is represented solely by the preliminary cash balance.
Material Changes and Unusual Items
The filing does not provide comparative financial data for the prior period to quantify material changes in revenue or profit. The primary financial disclosure is the preliminary cash balance, which is unaudited and subject to change upon the completion of the 2018 audited financial statements.
Guidance, Outlook, and Risks
- Clinical Update: The company issued a press release (Exhibit 99.1) announcing updated preliminary data on RX-3117 in pancreatic cancer.
- Forward-Looking Statements: The anticipated cash position is subject to risks and uncertainties, including changes based on final financial closing procedures.
- Legal Disclaimer: Information furnished under Item 2.02 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-K for the year ended December 31, 2018, as the $14.7 million figure is preliminary.
- Review the full text of the press release (Exhibit 99.1) for detailed clinical data on RX-3117.
- Confirm the company's full financial results (revenue, expenses, and net loss) once the audited statements are released.
- Check subsequent filings for any updates to the risk factors regarding the company's cash runway.